S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

NUVB Panacea Acquisition Corp

2.85

0.00 (0.00%)

Pre Market

Last Updated: 21:15:36

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Panacea Acquisition (NYSE:NUVB)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Panacea Acquisition Charts.

Panacea Acquisition (NYSE:NUVB)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Panacea Acquisition Charts.

Panacea Acquisition Corp News

Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference
Wednesday 27 November 2024 (2 weeks ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 14 November 2024 (4 weeks ago) • Edgar (US Regulatory)

Nuvation Bio to Present at the Jefferies London Healthcare Conference
Wednesday 13 November 2024 (4 weeks ago) • Business Wire

Form 8-K - Current report
Thursday 7 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 7 November 2024 (1 month ago) • Edgar (US Regulatory)

Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
Thursday 7 November 2024 (1 month ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Friday 11 October 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 10 October 2024 (2 months ago) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Thursday 10 October 2024 (2 months ago) • Edgar (US Regulatory)

Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer
Tuesday 8 October 2024 (2 months ago) • Business Wire

Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
Saturday 14 September 2024 (3 months ago) • Business Wire

Nuvation Bio to Present at the Cantor Global Healthcare Conference
Monday 9 September 2024 (3 months ago) • Business Wire

More Panacea Acquisition Corp News Articles

Sterling vs AUD

Invesco QQQ Trust Series 1

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions